[Clinical study of plasma substitute (Gelofusion) on fluid resuscitation in patients with burned shock].
OBJECTIVE
To investigate the effects of plasma substitute(Gelofusion) on fluid resuscitation in patients with burned shock.


METHODS
Twenty burn shock patients with total body surface area (TBSA) more than 40% were enrolled for clinical study on the effect of resuscitation with plasma substitute (Gelofusion). The patients were randomly divided into two groups: Gelofusion resuscitation group (n=11) and plasma resuscitation group (n=9). The cardiac output (CO),oxygen delivery (DO2), packed cell volume (PCV), blood and plasma viscosity, lactate(LA) and base deficit (BD) levels were detected at shock stage (postburn from 1 to 48 hours).


RESULTS
Two hours after rapid fluid replacement, the levels of CO and DO2 were gradually increased, while the levels of PCV, blood and plasma viscosity, LA and BD were markedly decreased (P<0.05 or P<0.01). After resuscitation, plasma viscosity in Gelofusion resuscitation group were obviously lower than that in plasma resuscitation group within 24 hours postburn (all P<0.05).With an exception of plasma viscosity, there were no significant differences in other parameters between two groups at various intervals (all P>0.05).


CONCLUSIONS
In the resuscitation of burn shock, the clinical effect of Gelofusion treatment is similar to that of plasma treatment. Gelofusion appears to be a fairly good plasma substitute for extensive application on the management of burn shock during the early stage.
Zhao
Xiao-dong
XD
Emergency Department, 304th Hospital of People's Liberation Army, Beijing 100037, China.
Dang
Wei
W
He
Zhong-jie
ZJ
Zhang
Xian
X
Yan
Bai-gang
BG
Yao
Yong-ming
YM
D000293:Adolescent; D000328:Adult; D002056:Burns / Q000150:complications / Q000628:therapy*; D005260:Female; D005780:Gelatin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012151:Resuscitation / Q000379:methods; D012769:Shock / Q000209:etiology / Q000628:therapy*; D013386:Succinates / Q000627:therapeutic use*; D055815:Young Adult
D013386:Succinates; C060085:succinylated gelatin; D005780:Gelatin